Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing ...

Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

Dementia, including Alzheimer’s disease and related disorders, is one of the fastest-growing public health concerns globally.

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Drugs originally developed to treat type 2 diabetes, particularly GLP-1 receptor agonists such as semaglutide (sold as ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American College of ...